Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

Panelists discuss how advanced practice providers (APPs) implement effective monitoring strategies for patients with chronic myeloid leukemia (CML), including regular check-ins after starting new ...

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical work with patients involved in trials.

Educating patients on the “risks and benefits” of clinical trials is a part of the pipeline for better treatment options in myeloproliferative neoplasms (MPNs) in which nurses can engage, said a nurse ...

In accordance with CMS quality measures, interventions like provider/patient education and better access to care help reduce ED visits after chemotherapy. A 10-pronged intervention strategy including ...

This expert panel features Dr Javier Pinilla, a senior member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida, and Lauren Verity Moore, a doctorally prepared nurse ...

The 2025 Extraordinary Healer® Award was presented during the 50th Annual Oncology Nursing Society Congress, recognizing oncology nursing professionals' dedication and impact. CURE Media Group and ...

Panelists discuss how the new FDA-approved formulation of nilotinib offers significant advantages over the original version by eliminating fasting requirements, potentially improving patient adherence ...

The FDA approved larotrectinib for use in adult and pediatric patients with NTRK fusion-positive solid tumors with few other options. The FDA approved larotrectinib (Vitrakvi) for use in adult and ...